Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 30;14(7):1387. doi: 10.3390/pharmaceutics14071387

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Maturation of bone-marrow-derived CD103⁺ DCs after transfection with LAH4-L1 (L1)- or LAH4-L1R (L1R)-formulated tOVA mRNA. CD103⁺ DCs were left untreated (UTX) or transfected on day 13 with mRNA encoding tOVA (unmodified, RNA/modified, MOD), or without mRNA (MOCK). The next day, cells were harvested and stained for DC markers and the maturation markers CD86 and CD40. Percentage CD40 and CD86 expression within the CD11c⁺ CD103⁺ DCs (a); cells were treated with LPS or R848 as a positive control; positive control for transfection was performed with jetMessenger^® (JM); positive control for antigen presentation where DCs were pulsed with SIINFEKL (SII). Overlay graphs for CD40 and CD86 expression (b); one representative result. n = 6; each dot represents one replicate, mean ± SD. One-way ANOVA, Tukey’s multiple comparison test: **** p < 0.0001 compared to the untreated cells; #### p < 0.0001 compared to jetMessenger^®-mRNA.